Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
November 2, 2020 4:01 PM EST Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets
 U.S. Product Revenue Increased Five-fold During the Third Quarter
 ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid and ezetimibe) in Germany, the Largest European Market
Conference Call and Webcast today, November 2nd at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2020, and... More
